We are Sorry, This Page doesn't Exist
CymaBay announces IND to commence clinical study of seladelpar
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
CymaBay announces results related to seladelpar clinical development program
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
CymaBay announces results from Phase 2 seladelpar study at ILC
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
CymaBay announces two presentations from Phase 2 study of seladelpar at AASLD
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
CymaBay announces early completion of enrollment for seladelpar study
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
CymaBay announces inducement grant under Nasdaq listing rule
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
CymaBay upgraded to Buy following expert panel on seladelpar hold at Stifel
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Engine Capital tells CymaBay to liquidate if Seladelpar can"t move forward
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
CymaBay to reduce workforce by 60%, end studies of seladelpar in PBC
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
CymaBay double downgraded at Raymond James after seladelpar setback
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
CymaBay Halts Study On Lead Clinical Program, Stock Crashes
CymaBay Therapeutics Inc (NASDAQ: CBAY) shares are losing more than 75% of their value Monday after the company said it's halting the development of its lead drug, seladelpar. 0 read more.....»»
Stifel downgrades CymaBay to Hold with $4 price target after seladelpar halted
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
CymaBay shares fall 77% on halted trial
Shares of CymaBay Therapeutics Inc. are down 77% in premarket trading after the biopharmaceutical company ended two studies and halted a third for its experimental drug seladelpar. CymaBay had been testing the therapy as a treatment for non-alcoholic .....»»
CymaBay announces departure of Chief Medical Officer Pol Boudes
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
CymaBay And Seladelpar In Phase 3 PBC: The Sprint To The Finish Line
CymaBay And Seladelpar In Phase 3 PBC: The Sprint To The Finish Line.....»»
CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study
CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat. .....»»
Amgen announces recommended public cash offer to Nuevolution for SEK 32.50
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Is CymaBay Therapeutics’ Liver Disease Trial Sunk?
CymaBay Therapeutics shares were nearly halved early Tuesday after the company provided an update from its midstage study of seladelpar for the treatment of nonalcoholic steatohepatitis......»»
CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors
Shares of CymaBay Therapeutics Inc. plummeted 43% in premarket trade Tuesday after the biotech said data from an ongoing Phase 2 trial showed patients with nonalcoholic steatohepatitis (NASH) who were treated with investigational drug seladelpar did n.....»»
CymaBay reports topline 12-week data from ongoing Phase 2b study of seladelpar
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»